Multiple sclerosis patients treated with dimethyl fumarate (Tecfidera) showed a reduced proportion of pro-inflammatory types of gut bacteria and an increased growth of "good" bacteria after three months of treatment.
Lecanemab, an amyloid-clearing monoclonal antibody drug shows positive results in the treatment of Alzheimer's disease. The drug is now poised for FDA approval early in 2023. Lecanemab slows cognitive decline by 27%.
Media coverage of the FDA-approved Alzheimer's drug aducanumab made the public less willing to volunteer in Alzheimer's pharmaceutical trials.
Taking NSAIDs such as ibuprofen or naproxen for arthritis may make inflammation worse over time, a new study reports.
People over the age of 45 who use anti-hyperglycemic medications to control their Type 2 diabetes are at increased risk of developing multiple sclerosis. However, those who are under 45 and take anti-hyperglycemic medications are at reduced risk of MS.
Lisdexamfetamine (Vyvanse), a medication commonly used to treat ADHD, lowers the risk of hospitalization and death for those with amphetamine use disorder.
A new implantable pump system safely and effectively bypasses the blood-brain barrier to deliver chemotherapy drugs to those with glioblastoma brain cancer.
A newly developed vaccine blocks the ability of the opioid Fentanyl's ability to enter the brain, thus blocking the drug's "high".
A new study reports regular usage of medications to control type 2 diabetes and lower cholesterol may decrease the risk of developing age-related macular degeneration.
Opioid withdrawal cuts off the supply of serotonin to the nucleus accumbens, dramatically reducing sociability in mice and increasing social aversion.
Black people are almost twice as likely to develop Alzheimer's disease later in life than white people. Researchers report Telmisartan, a drug used to treat high blood pressure by blocking angiotensin II, appears to be helpful in preventing or treating Alzheimer's disease in Black individuals. The drug did not show the same potential in white people.
An intranasally delivered oxytocin derivative helped improve cognitive function and reduced cognitive impairment in mouse models of Alzheimer's disease.
